INTRODUCTION
Chromosomal aberrations are found in approximately 55% of adult patients with acute myeloid leukemia (AML) and constitute the most important prognostic factor.
1,2 Aberrations conferring a poor prognosis were subsumed as adverse risk in the European Leukemia Net (ELN) classification.
1 This group includes complex karyotypes.
1,2 Monosomal karyotypes are associated with a dismal prognosis, even in complex karyotype AML. 3 Recent analyses suggest that allogeneic stem-cell transplantation (ASCT) in first complete remission confers a survival advantage to patients with AML with intermediate-and adverse-risk cytogenetics. 4 However, the course of patients with 17p abnormalities seems to remain dismal even after ASCT. 5, 6 Clonal heterogeneity within malignancies has been implicated as a driving mechanism of tumor development and progression because a high degree of genetic variability is associated with an increased risk of particular subclones having a proliferative advantage leading to clonal expansion. The existence of clonal heterogeneity has been documented for a variety of malignancies. [7] [8] [9] [10] [11] At the molecular level, clonal diversity seems to be associated with more aggressive disease. 8, 11, 12 In hematologic malignancies, studies on the role of clonal heterogeneity have focused on pediatric acute lymphoblastic leukemia (ALL). In this disorder, an ancestor clone often gives rise to several subclones, with some of them becoming extinct while others lead to further subclonal diversification. [13] [14] [15] Analysis of ALL relapse samples revealed that the relapse clone often originated from a minor subclone at diagnosis, suggesting that a subclone responsible for ALL relapse is selected for during treatment. 13 Clonal architecture and mechanisms of clonal evolution are less well understood in AML. Early cytogenetic studies have demonstrated karyotype evolution at disease relapse. 16, 17 In addition to confirming these results at the gene mutation level, whole-genome sequencing approaches recently revealed that, similar to ALL, already at diagnosis often several subclones derived from one founder clone are present. 18, 19 At relapse, either the founding clone gained additional mutations and expanded or a minor subclone of the founding clone survived therapy, gained mutations, and evolved into the relapse clone. Using cytogenetic data from two consecutive, large, randomized trials, we report here an in-depth analysis of the occurrence, ancestral relation patterns, and prognostic impact of cytogenetic subclones in previously untreated patients with AML.
PATIENTS AND METHODS

Patients
This analysis included all patients enrolled onto the two consecutive, prospective, randomized, multicenter AML96 and AML2003 trials of the German Study Alliance Leukemia. 20, 21 Patients had confirmed non-M3 AML and were previously untreated. Both studies included patients with prior myelodysplastic syndrome (MDS), refractory anemia with excess blasts MDS, and therapy-related AML (t-AML). All adult patients were eligible for the AML96 trial. Age was restricted to 16 to 60 years in the AML2003 trial. The studies were approved by the ethics committees of the participating centers. Patients gave written informed consent in accordance with the Declaration of Helsinki. Both studies were registered at www.clinicaltrials.gov (AML96, NCT00180115; AML2003, NCT00180102).
Treatment
The AML96 and AML2003 study protocols have been reported previously. 20, 21 In the AML96 trial, patients Յ 60 years old received double induction followed by three consolidation cycles for low-risk patients and related ASCT for intermediate-risk patients younger than age 55 years with a sibling donor or autologous stem-cell transplantation if no related donor was available. Unrelated donor ASCT was offered to adverse-risk patients younger than 45 years without a related donor. Patients older than 60 years received double induction and consolidation with either ASCT or chemotherapy.
Induction treatment in the AML2003 trial consisted of two courses of a 3ϩ7 regimen. In the standard arm, low-risk patients received three cycles of consolidation chemotherapy. Intermediate-risk patients received ASCT if a related donor was available. Otherwise, they proceeded with standard consolidation chemotherapy. Adverse-risk patients without related donor were assigned to unrelated ASCT as first choice.
Cytogenetic Testing
Classic karyotyping of metaphases was performed according to routine protocols. In total, 1,653 (88.8%) of 1,862 patients in the AML96 trial and 986 (83.4%) of 1,182 patients in the AML2003 trial were evaluable. To avoid bias, interphase fluorescence in situ hybridization and molecular diagnostic tests were not considered for this analysis. Documentation of cytogenetic aberrations followed the International System for Human Cytogenetic Nomenclature guidelines.
22 Accordingly, chromosomal gains or structural aberrations had to be detected in at least two metaphases and chromosomal losses in three metaphases to be acknowledged as clonal. These thresholds were applied to the karyotypes as a whole, but not to single unequivocally related subclones. Karyotypes were classified as composite karyotypes when clonal heterogeneity was too complex to allow enumeration of individual subclones. To assure that comparable criteria were applied, all karyotypes with less than four aberrations, which had initially been designated as composite, were re-evaluated for more accurate specification of subclones. Complex aberrant karyotypes were defined by at least three cytogenetic aberrations. Monosomal karyotypes were classified according to Breems et al, 3 and adverse-risk karyotypes were classified according to ELN criteria. 1 The genetically most evolved clone was chosen in case of clonal heterogeneity. Constitutional karyotypes were not counted as aberrant. 23 Adjusted P Յ .05 was considered to be significant. In univariate survival analyses, the prognostic value of subclone formation was analyzed for the outcomes of event-free survival (EFS) and overall survival (OS), which were measured from the start of therapy until death and from the start of therapy until event (death from any cause, therapy failure, or relapse), respectively. EFS was additionally censored at the time of ASCT. Kaplan-Meier survival curve estimates and corresponding log-rank tests were computed based on the combined data sets of AML96 and AML2003, based on the data from each study separately, and based on AML96 patients younger and older than 60 years. Multivariate survival analysis was done using Cox proportional hazards models including variables describing subclone formation (defined subclones, composite karyotype), presence of an adverse-risk karyotype, antecedent MDS, t-AML, and age. P Յ .05 was considered to be significant. The influence of ASCT on OS was analyzed by landmark analyses at landmark points of 3 and 6 months. 24 The statistical analysis was performed using R version 2.14.0 (www.r-project.org).
RESULTS
Subclones were detected in 418 (15.8%) of 2,639 evaluable patients. Among them, 252 (9.5%) of 2,639 patients displayed a defined number of subclones, whereas 166 (6.3%) of 2,639 patients were subsumed as having composite karyotypes. When only aberrant karyotypes were considered, the subclones were present in 418 (32.8%) of 1,274 patients, with 19.8% and 13.0% of patients having defined subclones and composite karyotypes, respectively. Subclone formation occurred in all cytogenetic risk categories (Table 1) and was particularly frequent in adverse-risk karyotype AML (51.2%) according to the ELN classification. 1 The highest rates of occurrence were found in the adverserisk subgroups with complex aberrant, monosomal, abnl(17p), and inv(3)/t(3,3) karyotypes, which harbored subclones in 69.0%, 67.1%, 64.8%, and 40.6% of patients, respectively. In complex aberrant AMLs with Ն five aberrations according to the Medical Research Council classification, 2 the subclone frequency was even higher (74.0%). In contrast, in core binding factor (CBF) and intermediate-risk AML with aberrant karyotypes, subclone formation was less frequent and predominantly occurred as few defined subclones, whereas in complex karyotype AML, often many subclones subsumed as composite karyotypes were found.
The clinical characteristics of patients with AML with subclone formation are listed in Table 2 compared with patients with aberrant karyotype AML without subclones. Patients with subclone formation were older (P Ͻ .001) and more frequently had an antecedent MDS (P Ͻ .001). This was also reflected by a lower leukocyte count (P Ͻ .001) and bone marrow blast percentage (P ϭ .03) at first diagnosis. The frequencies of FLT3 internal tandem duplications and NPM1 mutations were low in subclone patients (P ϭ .02). Importantly, subclone association with clinical parameters was most pronounced for composite karyotypes.
For the 252 patients with defined subclones, the ancestral clonal evolution patterns and their respective frequencies are shown in Figure 1. In patients with two subclones (Fig 1A) a mother-daughter pattern prevailed, with the second subclone displaying all cytogenetic aberrations of the first clone plus additional aberration(s), which set it apart as a distinct subclone. In some cases, however, both subclones were related and harbored common cytogenetic aberrations suggestive of a common ancestry, but both had acquired additional aberrations on their own. On the contrary, detection of two completely unrelated clones was rare (n ϭ 7). Among patients with three or more subclones (Figs 1B to 1D), a branched pattern prevailed over a linear pattern of successive additional genetic aberrations. Obviously, composite karyotypes were not accessible to the analysis of ancestral patterns.
Typically, additional cytogenetic aberrations harbored by daughter subclones were the same aberrations known to often occur simultaneously in a single homogeneous clone. This is best exemplified in CBF leukemias, where t(8;21) and inv (16) are well defined as the respective primary cytogenetic aberrations. In t(8;21)-positive AML, daughter subclones are most frequently marked by loss of a gonosome (n ϭ 15), del(9q) (n ϭ 5), and del(7q) (n ϭ 2). These three aberrations are also frequently found in conjunction with t(8;21) in one clone, even in the same frequency order [loss of a gonosome, n ϭ 46; del(9q), n ϭ 11; and del(7q), n ϭ 6]. In inv(16)-positive leukemia, the top three subclone aberrations, ϩ22 (n ϭ 22), ϩ8 (n ϭ 9), and del(7q) (n ϭ 7), correspond to the top three aberrations occurring in addition to an inv(16) in a single clone (n ϭ 11, n ϭ 9, and n ϭ 5, respectively). Therefore, subclones with additional cytogenetic aberrations seem to be on a trajectory to new main clone aberrations, with the cytogenetically more evolved daughter clone outgrowing the original mother clone. Tetraploidization as another mechanism of subclone formation was detected in 19 (5%) of 418 patients.
In non-CBF AML, subclone formation was associated with inferior remission rates after induction chemotherapy (Appendix Table  A1 , online only). In the AML96 trial, karyotypes with defined subclones and composite karyotypes had complete remission (CR) plus CR with incomplete recovery (CRi) rates of approximately 30% compared with 40.5% in aberrant karyotypes without subclones (P ϭ .03; Data Supplement). In the AML2003 trial, the CRϩCRi rates were 37.3% for karyotypes with defined subclones and 22.4% for composite karyotypes compared with 45.7% for aberrant karyotypes without subclones (P ϭ .007). Similar effects were observed when CR rates instead of CRϩCRi rates were assessed. In patients with CBF AML, remission rates were high irrespective of subclone formation.
In the AML96 trial, patients with non-CBF subclone karyotypes had a worse EFS and OS compared with patients with non-CBF aberrant karyotypes without subclones (median EFS: 3.2 v 1.1 months, respectively; P Ͻ .0001; median OS: 9.9 v 5.7 months, respectively; P Ͻ .0001; Fig 2) . An adverse prognostic effect of subclone formation on OS was confirmed for both age subgroups of Յ 60 years and Ͼ 60 years (P ϭ .0001 and P ϭ .01, respectively). When subclone karyotypes were broken down into karyotypes with defined subclones and composite karyotypes, patients with composite karyotypes had an even worse prognosis (median EFS: 1.2 v 1.1 months, respectively; P ϭ .36; median OS: 7.1 v 4.8 months, respectively; P ϭ .002; Data Supplement). Among all non-CBF subclone patients, ASCT was performed in 41 (20.1%) of 204 patients.
In the AML2003 trial, the total group of patients with non-CBF subclone karyotypes (defined subclones ϩ composite karyotypes) showed a statistically significantly inferior EFS as compared with patients with no subclones (median EFS: 10.7 v 5.3 months, respectively; P ϭ .01; Fig 3A) , whereas only a trend for a worse prognosis was observed for OS (median OS: 22.0 v 11.6 months, respectively; P ϭ .13; Fig 3B) . However, when only composite karyotypes as readout for most pronounced subclone formation were considered, prognostic significance was observed for OS as well (median OS: 19.3 months for defined subclones v 7.2 months for composite karyotypes; P ϭ .01; Figs 3C and 3D) . Among all non-CBF subclone patients, ASCT was performed in 91 (65.9%) of 138 patients. Event-free (EFS) and overall survival (OS) in the AML96 trial depending on subclone formation excluding normal karyotypes and core binding factor acute myeloid leukemias: univariate analysis. (A, C, E) EFS and (B, D, F) OS rates depending on subclone formation for (A, B) the total patient group, (C, D) the age cohort Յ 60 years old (median EFS: 7.0 months for no subclones v 3.3 months for subclones; P Ͻ .001; median OS: 12.7 months for no subclones v 7.7 months for subclones; P Ͻ .001), and (E, F) the age cohort Ͼ 60 years old (median EFS: 1.0 month for no subclones v 0.9 months for subclones; P ϭ .13; median OS: 7.7 months for no subclones v 4.8 months for subclones; P ϭ .01).
Landmark analyses including all patients with non-CBF AML with aberrant karyotypes, stratified for the presence of subclones at landmark points of 3 and 6 months, revealed that patients with subclones benefited more from ASCT than patients without subclones. In the AML2003 trial, ASCT was able to overcome the adverse prognosis inherent in the ASCT group in subclone but not in nonsubclone karyotypes (P ϭ .96 v P ϭ .05 at the 6-month landmark; log-rank test).
Clonal heterogeneity did not affect EFS and OS in CBF leukemias (AML96: median EFS, 51.5 months for no subclones v 48.5 months for subclones; P ϭ .95; median OS, 135.4 v 104.7 months; P ϭ .92; AML2003: median EFS, not reached; P ϭ .95; median OS, not reached; P ϭ .67). When non-CBF aberrant karyotypes were stratified into intermediate-risk AML and adverse-risk karyotypes, subclone formation played no prognostic role in intermediate-risk AML (AML96: median EFS, 4.4 v 6.9 months; P ϭ .87; median OS, 13.7 v 12.2 months; P ϭ .95; AML2003: median EFS, 12.9 v 10.2 months; P ϭ .33; median OS, 34.1 v 21.7 months; P ϭ .65). In contrast, in adverserisk AML, subclone formation was of additional prognostic significance in the AML96 trial (AML96: median EFS, 2.7 v 0.9 months; P ϭ .002; median OS, 7.4 v 5.0 months; P ϭ .009; AML2003: median EFS, 6.3 v 4.5 months; P ϭ .94; median OS, 10.8 v 9.0 months; P ϭ .54; Data Supplement).
To confirm the independent prognostic impact of subclone formation, multivariate Cox regression analyses including defined subclones and composite karyotype as separate variables describing successive intensities of subclone formation, together with the established parameters of adverse-risk karyotype, antecedent MDS, t-AML, and age, were performed. Composite karyotypes as marker of pronounced subclone formation emerged as an independent prognostic variable for OS when all patients with non-CBF AML and aberrant karyotypes from both the AML96 and AML2003 trials were considered (P ϭ .04, Table 3 ). This finding was mainly a result of a prominent effect of subclone formation in patients Յ 60 years of age in the AML96 trial (P ϭ .004). When cytogenetic adverse-and intermediate-risk groups with aberrant karyotype according to the ELN classification were analyzed separately in this multivariate model, subclone formation was found to 
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DISCUSSION
This study establishes clonal heterogeneity at the cytogenetic level as a frequent phenomenon, particularly in complex, monosomal, abnl(17p), and inv(3)/t(3,3) karyotype AML. Although in CBF and intermediate-risk AML with aberrant karyotype, subclone formation had no prognostic impact, clonal heterogeneity was an independent adverse prognostic marker in adverse-risk AML. ASCT improved the prognosis of patients with subclone karyotypes.
Subclonal diversification in AML so far has been detected by sequencing techniques at a molecular level. 18, 19 To allow for the analysis of occurrence and impact of subclone formation in large and well-characterized AML patient cohorts, our study takes advantage of metaphase karyotyping data, which also provide information on subclone formation, albeit with lower sensitivity. One caveat using this strategy might be misrepresentation of subclones as a result of selective proliferative (dis)advantage during shortterm in vitro culture required for metaphase generation.
Subclones, in most cases, showed related karyotypes. A model of clonal evolution is best illustrated in CBF leukemias, where daughter clones arise by gaining additional chromosomal aberrations and, if hereby put at a proliferative advantage, expand to outgrow the mother clone. In this model of clonal evolution, subclone formation is a transitory phenomenon on the way to a more complex karyotype, with the most frequent subclonedefining aberrations being identical to those detectable as additional aberrations in a single homogeneous clone. These findings fit the concept of leukemogenesis as a process with stepwise acquisition of genetic aberrations, leading to initiation and progression of the disease. 25, 26 If three or more subclones are detectable, they typically form a branched rather than a linearly successive ancestral pattern. This subclonal architecture is highly reminiscent of pediatric ALL.
13-15
Our study establishes clonal diversification as detected by metaphase karyotyping as an adverse prognostic marker in adverse-risk AML. Although there was considerable overlap with cytogenetic adverse-risk karyotypes, likely because subclone formation causes complex karyotype aberrations, clonal heterogeneity still held up as an independent adverse prognostic marker in a multivariate analysis including adverse-risk karyotype as covariable and a multivariate analysis of the adverse-risk subgroup. Thus, clonal heterogeneity adds prognostic information by itself and does not merely reflect the poor prognosis of established high-risk criteria. The prognostic impact of subclone formation was most pronounced in patients Յ 60 years old, likely because the overall poor prognosis of patients older than 60 years attenuated the effect of subclone formation in this age cohort.
Contrary to adverse-risk AML, subclone formation does not seem to worsen prognosis in CBF and intermediate-risk leukemias. In CBF AML, this is in tune with the finding that additional aberrations generally also exert no relevant negative prognostic impact.
2,27
Homogenous aberrant karyotypes, karyotypes with defined subclones, and composite karyotypes can be aligned into a spectrum of increasing clonal heterogeneity. Markedly, patients with a composite karyotype had a worse prognosis than patients with few defined subclones, which suggests that not only subclone formation is an adverse prognostic factor, but that prognosis also worsens with increasing clonal diversification. Biologically, the poor prognosis of subclone formation may be a result of a higher risk of developing resistance to chemotherapy, with individual subclones surviving treatment and causing relapse. This sequence of events has recently been demonstrated in AML by molecular studies. 18, 28 It is widely acknowledged that patients with AML with cytogenetic adverse risk benefit from ASCT. [29] [30] [31] [32] [33] Our results suggest that in adverse-risk AML, ASCT is particularly beneficial for patients harboring cytogenetic subclones. In the AML96 trial, ASCT was performed in only 20.1% of non-CBF subclone patients, whereas 65.9% of non-CBF subclone patients received ASCT in the AML2003 trial, thereby possibly explaining the less pronounced negative prognostic impact of subclone formation in this study. It is likely that ASCT, with its immunologic mechanism of action, 34 is also effective in clonally heterogeneous disease, whereas chemotherapy may fail to eradicate all subclones. Therefore, ASCT might overcome chemotherapy resistance conferred by clonal diversification.
Together, this is the first study showing that clonal heterogeneity is an adverse prognostic marker in AML and suggests a marked benefit for ASCT in patients with subclone formation. Although these observations require confirmation by other groups, clonal heterogeneity might hold promise to further refine cytogenetic risk stratification in adverse-risk AML. NOTE. Given the rareness of composite karyotypes in CBF leukemias, defined subclone karyotypes and composite karyotypes are subsumed for this entity.
Reported P values are adjusted for multiple testing. Abbreviations: AML, acute myeloid leukemia; CBF, core binding factor; CR, complete remission; CRi, complete remission with incomplete recovery. 
